Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin's Lymphoma
Interventions: Entospletinib, Idelalisib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 13
States / cities: La Jolla, California • Long Beach, California • Oxnard, California + 10 more

Conditions: Type2 Diabetes, Glucose, High Blood
Interventions: Mediterranean Diet, Low-fat diet; Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insulin Resistance, Obesity
Interventions: Sleep extension; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Kidney Transplantation
Interventions: Inhaled Carbon Monoxide; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Cirrhotic Cardiomyopathy
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Nashville, Tennessee • Dallas, Texas

Conditions: Spinal Cord Injuries, Spine Disease, Stroke
Interventions: Lidocaine Cream 5%, Rehabilitation Movement Training; Drug · Other
Lead sponsor: University of Texas Rio Grande Valley; Other
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Harlingen, Texas

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Opioid Growth Factor (OGF); Drug · Biological
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Allentown, Pennsylvania • Hershey, Pennsylvania

Conditions: High Grade Glioma
Interventions: PET-MRI Brain Scan, Blood draw, Memory testing, Optional lumbar puncture for cerebrospinal fluid collection; Procedure · Diagnostic Test · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cardiovascular Diseases, Breast Cancer, Prostate Cancer, Physical Inactivity
Interventions: Gamification and Social Support, Attention control; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Duarte, California • Philadelphia, Pennsylvania

Conditions: Conjunctival Staining
Interventions: Complete Easy Rub, ReNu MultiPlus, Clear Care, Contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Diffuse Systemic Sclerosis
Interventions: Fresolimumab; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Inhaled Cannabis, Oral THC, Oral Placebo, Inhaled placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Interventions: Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: San Carlos, California • Hartford, Connecticut • Norwalk, Connecticut + 9 more

Conditions: Bioavailability
Interventions: Risedronate; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Fort Myers, Florida • Miramar, Florida • Austin, Texas

Conditions: Nephropathy
Interventions: Oral N-Acetylcysteine, Sodium Bicarbonate; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Multiple Sclerosis
Interventions: Ozanimod; Drug
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Interventions: Investigational Liver Fat Quantification Software; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 5 Years to 21 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Altitude Sickness
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Idiopathic Nephrotic Syndrome
Interventions: Standard of Care, UrApp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon

Conditions: Obstructive Sleep Apnea, Alzheimer's Disease
Interventions: Continuous positive airway pressure device; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 30 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Epilepsy, Seizures
Interventions: Perampanel; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Heavy Menstrual Bleeding
Interventions: Sparrow Link, Sparrow Link (Sham); Device
Lead sponsor: Spark Biomedical, Inc.; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Graft vs Host Disease
Interventions: Pregnyl®; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 76 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

The TCF7L2 Gene: Dietary Prevention of T2DM

Metabolic Effects of Sleep Extension in People With Obesity

Safety and Tolerability Study of Inhaled Carbon Monoxide in Kidney Transplant Patients

Prospective Investigation of Cirrhotic Cardiomyopathy in Humans

Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI

Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients

Fresolimumab In Systemic Sclerosis

Cannabis for Spasticity in Multiple Sclerosis

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate

Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS

Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study

Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)

Brain Sleep Clearance of Amyloid-Beta Peptides

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

Delivering tAN to Reduce HMB: The LUNA Study

IL-17 Neutrophils in CF Lung Inflammation

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD